# Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

> **NCT05047185** · PHASE2 · COMPLETED · sponsor: **Pharvaris Netherlands B.V.** · enrollment: 34 (actual)

## Conditions studied

- Hereditary Angioedema
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- Hereditary Angioedema Types I and II
- Hereditary Angioedema Attack
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- C1 Esterase Inhibitor Deficiency
- C1 Inhibitor Deficiency

## Interventions

- **DRUG:** Deucrictibant low dose
- **DRUG:** Deucrictibant high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05047185
- **Lead sponsor:** Pharvaris Netherlands B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-19
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05047185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05047185, "Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05047185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*